BAGNEUX, France--(BUSINESS WIRE)--Genomic Vision (Paris:GV) (FR0011799907 – GV / PEA-PME eligible), a molecular diagnostics company specialized in the development of diagnostic tests for genetic diseases and cancers based on molecular combing, today announces that it has signed an amendment to its contract with Quest Diagnostics to extend their strategic collaboration based on Genomic Vision's technology. The amendment extends the collaboration for three more years, until November 2018.
Under the terms of the amendment, Quest Diagnostics retains exclusive rights to develop, validate and market tests based on molecular combing in the fields of breast and ovarian cancer, such as BRCA gene mutation testing, hereditary colon cancer (Lynch syndrome), spinal muscular atrophy (SMA) and facioscapulohumeral muscular distrophy (FSHD) in the United States, India and Mexico.
Help employers find you! Check out all the jobs and post your resume.
Under the terms of the amendment, Quest Diagnostics retains exclusive rights to develop, validate and market tests based on molecular combing in the fields of breast and ovarian cancer, such as BRCA gene mutation testing, hereditary colon cancer (Lynch syndrome), spinal muscular atrophy (SMA) and facioscapulohumeral muscular distrophy (FSHD) in the United States, India and Mexico.
Help employers find you! Check out all the jobs and post your resume.
